Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Core Insights - Aprea Therapeutics is hosting a virtual KOL event on June 24, 2024, to discuss APR-1051, a selective oral WEE1 inhibitor [1][2] - The event will feature presentations from experts in medicinal chemistry and cancer biology, focusing on the drug's design and preclinical findings [1][4] - APR-1051 is currently in a Phase 1 trial as a monotherapy for patients with significant unmet medical needs, particularly those with Cyclin E overexpression [2] Company Overview - Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, specializing in precision oncology through synthetic lethality [5] - The company's lead program is ATRN-119, an ATR inhibitor in development for solid tumor indications, alongside APR-1051, which has recently entered clinical trials [5] Expert Contributions - Joseph Vacca, PhD, a medicinal chemistry expert with a significant background in drug development, will discuss the medicinal chemistry history and preclinical findings of APR-1051 [1][3] - Eric J. Brown, PhD, an Associate Professor at the University of Pennsylvania, will present on preclinical findings related to the WEE1 inhibitor class and its implications for cancer therapy [1][4]